ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Part of paid clinical trials in Costa Mesa, California.
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Study ID
- NCT06194799
- Phase
- PHASE3
- Status
- Enrolling By Invitation
Conditions
- Alzheimer's Disease Psychosis
Eligibility Criteria
- Sex
- ALL
- Age
- 55 Years - 95 Years
- Healthy Volunteers
- Not accepted
Interventions
- ACP-204 — DRUGACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule
Study Details
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Key Dates
- First listed
- Jan 8, 2024
- Start date
- Apr 23, 2024
- Status verified
- Dec 2025
- Primary completion
- Apr 30, 2029
- Completion
- May 31, 2029
Study Design
- Enrollment
- 752 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: ACP-204ACP-204 30mg or 60mg
Primary Outcome Measure
Treatment-emergent adverse events [ Time Frame: 52 Weeks ]
Locations (21)
Find similar trials in Costa Mesa, CA
Related Studies
- ACP-204 in Adults With Alzheimer's Disease PsychosisPHASE2/PHASE3 · Recruiting · ACADIA Pharmaceuticals Inc. · Chandler, Arizona